Compare Hormel Foods Corp (HRL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Hormel Foods Corp trades at $24.3 (market cap $13.37B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Hormel Foods Corp pays a 4.81% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hormel Foods Corp nearer its low. Which is the better fit depends on your goals.
| HRL | XBI | |
|---|---|---|
Market Cap | $13.37B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $29.25 | $164.28 |
52-Week Low | $19.74 | $86.92 |
Enterprise Value | $15.37B | — |
Dividend Yield | 4.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $24.41, down 1.21% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 28.6x and modest 3.8% net margin, while revenue has been stable around $12B annually. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
HRL offers defensive appeal with consistent dividends and a 4.6% yield, but faces margin pressure and modest growth prospects. Analyst consensus is Hold with a $26.33 price target, suggesting limited upside. Key risks include consumer spending sensitivity and execution challenges under new leadership.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
